Sangamo Therapeutics (SGMO) Cash & Current Investments (2016 - 2025)
Historic Cash & Current Investments for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to $30.5 million.
- Sangamo Therapeutics' Cash & Current Investments fell 2212.44% to $30.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.5 million, marking a year-over-year decrease of 2212.44%. This contributed to the annual value of $41.9 million for FY2024, which is 726.93% down from last year.
- Per Sangamo Therapeutics' latest filing, its Cash & Current Investments stood at $30.5 million for Q3 2025, which was down 2212.44% from $38.3 million recorded in Q2 2025.
- Sangamo Therapeutics' 5-year Cash & Current Investments high stood at $587.1 million for Q1 2021, and its period low was $25.2 million during Q1 2025.
- In the last 5 years, Sangamo Therapeutics' Cash & Current Investments had a median value of $100.4 million in 2022 and averaged $190.6 million.
- In the last 5 years, Sangamo Therapeutics' Cash & Current Investments skyrocketed by 6393.04% in 2021 and then plummeted by 8058.29% in 2024.
- Sangamo Therapeutics' Cash & Current Investments (Quarter) stood at $376.5 million in 2021, then plummeted by 73.33% to $100.4 million in 2022, then tumbled by 55.0% to $45.2 million in 2023, then decreased by 7.27% to $41.9 million in 2024, then decreased by 27.17% to $30.5 million in 2025.
- Its Cash & Current Investments was $30.5 million in Q3 2025, compared to $38.3 million in Q2 2025 and $25.2 million in Q1 2025.